Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study

in European Journal of Endocrinology
View More View Less
  • 1 Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg University, Strasbourg, France
  • 2 Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, CIC-1421, Regional Pharmacovigilance Center INSERM, Sorbonne Universités, Paris, France

Correspondence should be addressed to L Arnaud; Email: laurent.arnaud@chru-strasbourg.fr
Restricted access

Objective

Atrial fibrillation (AF) may be triggered by intravenous bisphosphonates (IVBPs) such as zoledronic acid or pamidronic acid. Our objective was to confirm the association between AF and IVBPs in a real-life large pharmacovigilance database.

Design

A systematic analysis of VigiBase, the World Health Organization's pharmacovigilance database.

Methods

Analysis of adverse events reported as ‘atrial fibrillation’ (according to the Medical Dictionary for Drug Regulatory Activities) associated with the use of zoledronic acid or pamidronic acid, in VigiBase, the World Health Organization's global Individual Case Safety Report (ICSR) database. All ICSRs reporting AF associated with zoledronic acid or pamidronic acid were included in a disproportionality analysis determining the lower end of the 95% credibility interval for the information component (IC025), showing a statistical association when >0.

Results

530 ICSRs reporting on the association between AF and IVBPs were extracted. Bayesian disproportionality analysis detected a significant association between AF and use of zoledronic acid (IC025 = 1.83) and pamidronic acid (IC025 = 2.16). Further analysis of these ICSRs determined that AF was severe in 85.0% of cases and with a mortality of 17.7%. The risk of severe AF was increased (OR: 2.98 (95% CI: 1.17–7.57), P = 0.02) following zoledronic acid vs pamidronic acid, after adjustment for age and gender.

Conclusions

This is the first VigiBase pharmacoepidemiological study confirming the association between IVBPs and AF. Most AF were severe, with a high frequency of lethal outcome. The risk of severe AF was increased following zoledronic acid use compared to pamidronic acid, advocating for a cautious use of IVBPs.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 281 281 281
Full Text Views 27 27 27
PDF Downloads 13 13 13
  • 1

    Zoni-Berisso M, Lercari F, Carazza T & Domenicucci S Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology 2014 6 213220. (https://doi.org/10.2147/CLEP.S47385)

    • Search Google Scholar
    • Export Citation
  • 2

    Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M & Zimetbaum P Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value in Health 2006 9 348356. (https://doi.org/10.1111/j.1524-4733.2006.00124.x)

    • Search Google Scholar
    • Export Citation
  • 3

    Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A & Sigamani A Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 2016 388 11611169. (https://doi.org/10.1016/S0140-6736(1630968-0)

    • Search Google Scholar
    • Export Citation
  • 4

    Russell RGG Bisphosphonates: the first 40 years. Bone 2011 49 219. (https://doi.org/10.1016/j.bone.2011.04.022)

  • 5

    Wysowski DK & Greene P Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone 2013 57 423428. (https://doi.org/10.1016/j.bone.2013.09.008)

    • Search Google Scholar
    • Export Citation
  • 6

    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC & Man Z Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007 356 18091822. (https://doi.org/10.1056/NEJMoa067312)

    • Search Google Scholar
    • Export Citation
  • 7

    Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM & Lauer MS Inflammation as a risk factor for atrial fibrillation. Circulation 2003 108 30063010. (https://doi.org/10.1161/01.CIR.0000103131.70301.4F)

    • Search Google Scholar
    • Export Citation
  • 8

    Issac TT, Dokainish H & Lakkis NM Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. Journal of the American College of Cardiology 2007 50 20212028. (https://doi.org/10.1016/j.jacc.2007.06.054)

    • Search Google Scholar
    • Export Citation
  • 9

    Reid IR, Gamble GD, Mesenbrink P, Lakatos P & Black DM Characterization of and risk factors for the acute-phase response after zoledronic acid. Journal of Clinical Endocrinology and Metabolism 2010 95 43804387. (https://doi.org/10.1210/jc.2010-0597)

    • Search Google Scholar
    • Export Citation
  • 10

    Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, Turton J & Eberl M Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. Journal of Bone and Mineral Research 2013 28 464471. (https://doi.org/10.1002/jbmr.1797)

    • Search Google Scholar
    • Export Citation
  • 11

    Hewitt RE, Lissina A, Green AE, Slay ES, Price DA & Sewell AK The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clinical and Experimental Immunology 2005 139 101111. (https://doi.org/10.1111/j.1365-2249.2005.02665.x)

    • Search Google Scholar
    • Export Citation
  • 12

    Howard PA, Barnes BJ, Vacek JL, Chen W & Lai SM Impact of bisphosphonates on the risk of atrial fibrillation. American Journal of Cardiovascular Drugs 2010 10 359367. (https://doi.org/10.2165/11584720-000000000-00000)

    • Search Google Scholar
    • Export Citation
  • 13

    Tanvetyanon T & Stiff PJ Management of the adverse effects associated with intravenous bisphosphonates. Annals of Oncology 2006 17 897907. (https://doi.org/10.1093/annonc/mdj105)

    • Search Google Scholar
    • Export Citation
  • 14

    Dobrev D & Nattel S Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. Journal of Cardiovascular Pharmacology 2008 52 293299. (https://doi.org/10.1097/FJC.0b013e318171924d)

    • Search Google Scholar
    • Export Citation
  • 15

    Nattel S & Dobrev D The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. European Heart Journal 2012 33 18701877. (https://doi.org/10.1093/eurheartj/ehs079)

    • Search Google Scholar
    • Export Citation
  • 16

    Denham NC, Pearman CM, Caldwell JL, Madders GWP, Eisner DA, Trafford AW & Dibb KM Calcium in the pathophysiology of atrial fibrillation and heart failure. Frontiers in Physiology 2018 9 1380. (https://doi.org/10.3389/fphys.2018.01380)

    • Search Google Scholar
    • Export Citation
  • 17

    Pazianas M, Compston J & Huang CLH Atrial fibrillation and bisphosphonate therapy. Journal of Bone and Mineral Research 2010 25 210. (https://doi.org/10.1359/jbmr.091201)

    • Search Google Scholar
    • Export Citation
  • 18

    Abrahamsen B, Eiken P & Brixen K Atrial fibrillation in fracture patients treated with oral bisphosphonates. Journal of Internal Medicine 2009 265 581592. (https://doi.org/10.1111/j.1365-2796.2008.02065.x)

    • Search Google Scholar
    • Export Citation
  • 19

    Heckbert SR, Li G, Cummings SR, Smith NL & Psaty BM Use of alendronate and risk of incident atrial fibrillation in women. Archives of Internal Medicine 2008 168 826831. (https://doi.org/10.1001/archinte.168.8.826)

    • Search Google Scholar
    • Export Citation
  • 20

    Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, Homel P, Borer JS & Lichstein E Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. American Journal of Cardiology 2014 113 18151821. (https://doi.org/10.1016/j.amjcard.2014.03.008)

    • Search Google Scholar
    • Export Citation
  • 21

    Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH & Kim SC Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLOS ONE 2015 10 e0122646. (https://doi.org/10.1371/journal.pone.0122646)

    • Search Google Scholar
    • Export Citation
  • 22

    Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J & Aikat S Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest 2013 144 13111322. (https://doi.org/10.1378/chest.13-0675)

    • Search Google Scholar
    • Export Citation
  • 23

    Bhuriya R, Singh M, Molnar J, Arora R & Khosla S Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. International Journal of Cardiology 2010 142 213217. (https://doi.org/10.1016/j.ijcard.2009.11.041)

    • Search Google Scholar
    • Export Citation
  • 24

    Kim SY, Kim MJ, Cadarette SM & Solomon DH Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Research & Therapy 2010 12 R30. (https://doi.org/10.1186/ar2938)

    • Search Google Scholar
    • Export Citation
  • 25

    Mak A, Cheung MWL, Ho RCM, Cheak AAC & Lau CS Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskeletal Disorders 2009 10 113. (https://doi.org/10.1186/1471-2474-10-113)

    • Search Google Scholar
    • Export Citation
  • 26

    Loke YK, Jeevanantham V & Singh S Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Safety 2009 32 219228. (https://doi.org/10.2165/00002018-200932030-00004)

    • Search Google Scholar
    • Export Citation
  • 27

    Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A & De Freitas RM A Bayesian neural network method for adverse drug reaction signal generation. European Journal of Clinical Pharmacology 1998 54 315321. (https://doi.org/10.1007/s002280050466)

    • Search Google Scholar
    • Export Citation
  • 28

    Arnaud L, Lebrun-Vignes B & Salem JE Checkpoint inhibitor-associated immune arthritis. Annals of the Rheumatic Diseases 2019 78 e68. (https://doi.org/10.1136/annrheumdis-2018-213470)

    • Search Google Scholar
    • Export Citation
  • 29

    Mertz P, Lebrun-Vignes B, Salem JE & Arnaud L Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. Journal of Allergy and Clinical Immunology 2019 143 433436. (https://doi.org/10.1016/j.jaci.2018.09.001)

    • Search Google Scholar
    • Export Citation
  • 30

    Norén GN, Hopstadius J & Bate A Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Statistical Methods in Medical Research 2013 22 5769. (https://doi.org/10.1177/0962280211403604)

    • Search Google Scholar
    • Export Citation
  • 31

    Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM & Bonaca MP Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet. Oncology 2018 19 15791589. (https://doi.org/10.1016/S1470-2045(1830608-9)

    • Search Google Scholar
    • Export Citation
  • 32

    Farmakis D, Parissis J & Filippatos G Insights into onco-cardiology: atrial fibrillation in cancer. Journal of the American College of Cardiology 2014 63 945953. (https://doi.org/10.1016/j.jacc.2013.11.026)

    • Search Google Scholar
    • Export Citation
  • 33

    Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA & Cummings SR Relationship between osteoporosis and cardiovascular disease in postmenopausal women. Journal of Bone and Mineral Research 2005 20 19121920. (https://doi.org/10.1359/JBMR.050711)

    • Search Google Scholar
    • Export Citation
  • 34

    Maalouf NM, Heller HJ, Odvina CV, Kim PJ & Sakhaee K Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocrine Practice 2006 12 4853. (https://doi.org/10.4158/EP.12.1.48)

    • Search Google Scholar
    • Export Citation
  • 35

    Michel C, Scosyrev E, Petrin M & Schmouder R Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clinical Drug Investigation 2017 37 415422. (https://doi.org/10.1007/s40261-017-0503-6)

    • Search Google Scholar
    • Export Citation